Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMCgp100 (Kimmtrak) in Advanced Uveal Melanoma
NCT02570308Phase 2Completed
- Sponsor
- Immunocore
- Start
- Feb 2016
- Primary completion
- Mar 2020
- Modality
- Bispecific Antibodies, TCR-Engineered T Cells, Fc-Fusion Proteins
- Countries
- 5
01
Overview
A Phase 2 trial of tebentafusp in Uveal melanoma (UM), sponsored by Immunocore. Started Feb 2016; status: completed.
02
Drugs
tebentafusp
03
Conditions
Uveal melanoma (UM)
Beyond the preview
Go deeper on NCT02570308.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02570308.